1. Home
  2. KODK vs AKBA Comparison

KODK vs AKBA Comparison

Compare KODK & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Kodak Company

KODK

Eastman Kodak Company

N/A

Current Price

$8.88

Market Cap

834.8M

ML Signal

N/A

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$1.68

Market Cap

729.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KODK
AKBA
Founded
1880
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
834.8M
729.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
KODK
AKBA
Price
$8.88
$1.68
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$6.25
AVG Volume (30 Days)
1.5M
3.1M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,045,000,000.00
$225,071,000.00
Revenue This Year
N/A
$52.38
Revenue Next Year
N/A
$22.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.49
52 Week Low
$4.93
$1.45
52 Week High
$9.96
$4.08

Technical Indicators

Market Signals
Indicator
KODK
AKBA
Relative Strength Index (RSI) 60.02 43.79
Support Level $8.01 $1.61
Resistance Level $9.13 $1.73
Average True Range (ATR) 0.47 0.07
MACD -0.04 0.04
Stochastic Oscillator 45.22 57.50

Price Performance

Historical Comparison
KODK
AKBA

About KODK Eastman Kodak Company

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: